SMS Lifesciences Quarterly Results for Trading Insights
In Mar 2025, SMS Lifesciences (SMSLIFE) reported revenue ₹92 Cr and net profit ₹4 Cr. For annual financials, live price and key ratios, visit SMSLIFE stock price BSE.
SMSLIFE Quarterly Results — Revenue, Profit & EPS Highlights
SMS Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with SMSLIFE DCF to assess whether the stock is under or overvalued.
- Revenue of ₹92 Cr in Mar 2025 (+9.5% vs Jun 2025, +0.0% vs Mar 2024)
- Net Profit of ₹4 Cr in Mar 2025 (+0.0% vs Jun 2025, -42.9% vs Mar 2024)
- EBITDA of ₹10 Cr in Mar 2025 (-23.1% vs Jun 2025)
- Operating Margin of 8.0% in Mar 2025 (-6.0pp vs Jun 2025)
- Earnings Per Share of ₹9.83 in Mar 2025 (-28.5% vs Jun 2025)
SMS Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SMSLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2025 | Jun 2025 | Sept 2024 | Mar 2024 | Jun 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 92 | 84 | 81 | 92 | 93 | 9.5% | - |
| Net Profit (₹ Cr) | 4 | 4 | 3 | 7 | 7 | - | - |
| EBITDA (₹ Cr) | 10 | 13 | 11 | 14 | 17 | - | - |
| EPS (₹) | 9.83 | 13.75 | 15.46 | 19.53 | 23.15 | - | - |
| Operating Margin (%) | 8.0% | 14.0% | 11.0% | 13.0% | 18.0% | - | - |
SMSLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
SMS Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse SMSLIFE institutional holdings to track promoter, FII and institutional holdings.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SMSLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
SMS Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1747.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 134.4 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6432.5 | 2,860 | 689 | +7.1% | - | 24.1% | 247.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹139,344.76 Cr | 4182.9 | 3,219 | 591 | +11.3% | - | 18.4% | 238.5 |
|
Dr Reddys Laborator…
Sept 2025 |
₹109,930.83 Cr | 1354.6 | 9,135 | 1,337 | +1.1% | - | 14.6% | 83.7 |
|
Lupin
Sept 2025 |
₹104,941.69 Cr | 2302.7 | 6,921 | 1,485 | +23.2% | - | 21.5% | 71.2 |
All amounts in ₹ Crores